Vitura Health Past Earnings Performance
Past criteria checks 2/6
Vitura Health has been growing earnings at an average annual rate of 58.2%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 58.1% per year. Vitura Health's return on equity is 8.5%, and it has net margins of 2.8%.
Key information
58.2%
Earnings growth rate
96.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 58.1% |
| Return on equity | 8.5% |
| Net Margin | 2.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Vitura Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 124 | 4 | 29 | 0 |
| 31 Mar 24 | 122 | 6 | 27 | 0 |
| 31 Dec 23 | 120 | 9 | 25 | 0 |
| 30 Sep 23 | 119 | 12 | 23 | 0 |
| 30 Jun 23 | 117 | 14 | 20 | 0 |
| 31 Mar 23 | 107 | 12 | 19 | 0 |
| 31 Dec 22 | 97 | 10 | 19 | 0 |
| 30 Sep 22 | 82 | 8 | 17 | 0 |
| 30 Jun 22 | 67 | 6 | 16 | 0 |
| 31 Mar 22 | 54 | 5 | 12 | 0 |
| 31 Dec 21 | 42 | 5 | 8 | 0 |
| 30 Sep 21 | 32 | 3 | 6 | 0 |
| 30 Jun 21 | 22 | 1 | 5 | 0 |
| 31 Mar 21 | 15 | 0 | 5 | 0 |
| 31 Dec 20 | 7 | -2 | 5 | 0 |
| 30 Sep 20 | 4 | -3 | 5 | 0 |
| 30 Jun 20 | 0 | -4 | 4 | 0 |
| 31 Mar 20 | 0 | -4 | 4 | 0 |
| 31 Dec 19 | 0 | -4 | 3 | 0 |
| 30 Sep 19 | 0 | -3 | 3 | 0 |
| 30 Jun 19 | 0 | -3 | 3 | 0 |
| 30 Jun 18 | 0 | 0 | 0 | 0 |
| 30 Jun 17 | 0 | 0 | 0 | 0 |
Quality Earnings: 1CE0 has high quality earnings.
Growing Profit Margin: 1CE0's current net profit margins (2.8%) are lower than last year (11.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1CE0 has become profitable over the past 5 years, growing earnings by 58.2% per year.
Accelerating Growth: 1CE0's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1CE0 had negative earnings growth (-74.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (28.7%).
Return on Equity
High ROE: 1CE0's Return on Equity (8.5%) is considered low.